Startup profile for Cedar: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Cedar funding, valuation and investors

Patient financial engagement platform simplifying medical billing for health systems.

Keep track of Cedar

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series D

$200M · 2021

Latest known valuation

$3.2B

Series D · 2021

Total disclosed equity funding

$302M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth · New York, New York

Investors in latest funding

Lead: Tiger Global Management

Other: Andreessen Horowitz

Source links not recorded Last verified: 2026-07-25

Overview

Cedar provides patient financial engagement software for health systems — simplifying medical bills, payment plans, and billing communications to improve collections and patient experience.

Why Cedar is interesting

Category leader in patient-centric revenue cycle — Tiger-led D round with Thrive and Founders Fund alongside a16z.

Product & use cases

Patient financial engagement platform — clearer medical bills, flexible payment plans, and automated billing outreach for health systems.

  • Patient billing clarity and payment plan options
  • Healthcare revenue cycle patient engagement
  • Automated billing communications for hospitals

Key facts

  • Series D (2021): $200M led by Tiger Global at $3.2B valuation; a16z, Thrive participated (PR Newswire)
  • Series C (2020): $102M led by a16z; Thrive, Founders Fund among participants (Cedar press)

Funding history (newest first)

Series D

2021 $200M Valuation: $3.2B

Series C

2020 $102M

Investors in our directory

Funds linked from Cedar's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz Thrive Capital Tiger Global Management Founders Fund

Competitive landscape

Edge: Category leader in patient-centric revenue cycle — Tiger-led D round with Thrive and Founders Fund alongside a16z.

Cedar operates in healthtech, enterprise-saas. Category leader in patient-centric revenue cycle — Tiger-led D round with Thrive and Founders Fund alongside a16z.

  • Epic MyChart billing incumbent

    EHR-native patient billing.

  • Waystar adjacent

    Healthcare RCM platform.

  • Patientco direct

    Patient payment platform competitor.

Notable stories

  • Category leader in patient-centric revenue cycle.
  • Series D at $3.2B led by Tiger Global in 2021.

Industries

Healthtech Enterprise SaaS

FAQs about Cedar

Practical answers founders, operators, and investors typically search for.

Cedar helps hospitals and health systems present clearer medical bills, offer flexible payment options, and automate patient billing outreach — improving both collections and satisfaction.
Andreessen Horowitz (see /fund/andreessen-horowitz) led the $102M Series C in 2020. Tiger Global Management (see /fund/tiger-global-management) led the $200M Series D at $3.2B in 2021; Thrive Capital (see /fund/thrive-capital) and Founders Fund (see /fund/founders-fund) participated.
Growth stage after Series D ($200M, 2021 at $3.2B valuation). Cedar remains private.
Patient billing is a top complaint in U.S. healthcare — Cedar became a category leader in patient-centric revenue cycle, now embedded in major health-system workflows.
No — Cedar remains a private company.
Headquarters not publicly disclosed in sources we index.
Founding year not publicly disclosed in sources we index.
Cedar has not publicly disclosed profitability.
See fundraising rounds and highlights on this profile for disclosed amounts.
healthtech, enterprise-saas
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.